Home › Research › Biomarkers
Plasma Biomarkers and Clinical Outcomes in Early-Onset Dementia
Hyemin Jang, S I Lee, Hee Jin Kim, Na‐Yeon Jung, Henrik Zetterberg, Kaj Blennow, Liana G. Apostolova, So Young Moon et al.. JAMA Network Open, 2026-04-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
A total of 322 participants with p-tau217, GFAP, and NfL analyses were stratified into the EOAD or FTD group based on their diagnosis. The EOAD group (n = 245) had a mean (SD) age of 61.8 (5.4) years and included 163 females (66.5%), while the FTD group (n = 77) had a mean (SD) age of 65.1 (7.3) years and included 45 females (62.3%). In the EOAD group, higher log2-transformed baseline p-tau217, GFAP, and NfL were each associated with faster decline in the MMSE score (association estimate [SE], -0.390 [0.127], P = .002; -0.775 [0.164], P < .001; and -0.679 [0.182], P < .001, respectively) and the CDR-SB score (estimate [SE], 0.401 [0.099], P < .001; 0.535 [0.126], P < .001; and 0.693 [0.122], P < .001, respectively). In the FTD group, GFAP and NfL were associated with MMSE decline (estimate [SE], -2.118 [0.566], P < .001 and -2.360 [0.428], P < .001, respectively), whereas p-tau217 was not (estimate [SE], 0.071 [0.418], P = .87). No biomarker was associated with FTLD-modified CDR-SB score change. Longitudinally, all mean (SD) biomarker levels increased in the EOAD group (p-tau217: 0.253 [0.077] pg/mL, P = .001; GFAP: 0.173 [0.040] pg/mL, P < .001; NfL: 0.149 [0.045] pg/mL, P = .001), whereas in the FTD group, only NfL level showed an upward pattern (0.251 [0.127] pg/mL, P = .05). Annualized biomarker changes were associated with worsening clinical outcomes in the EOAD group, but not in the FTD group. GFAP and NfL level increases were associated with MMSE score decline (estimate [SE], -0.005 [0.002], P = .007 and -0.010 [0.003], P = .001, respectively), while p-tau217 level increases were associated with CDR-SB score worsening (estimate [SE], 0.072 [0.024], P = .003) in the EOAD group. Conclusions and Relevance: In this cohort study of patients with EOAD and FTD, baseline p-tau217, GFAP, and NfL were consistently associated with clinical outcomes in the EOAD group, whereas GFAP and NfL were associated with cognition only in the FTD group. These findings demonstrate distinct characteristics of plasma biomarkers in EOAD and FTD, supporting their potential utility for risk stratification.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 245 participants. In 245 people with early-onset Alzheimer's disease, higher baseline p-tau217, GFAP and neurofilament light were each linked to faster decline in cognitive scores, and all three markers rose over time. Reported effect size: 66.5%; 62.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jang, H., Lee, S. I., Kim, H. J., Jung, N., Zetterberg, H., Blennow, K., et al. (2026). Plasma Biomarkers and Clinical Outcomes in Early-Onset Dementia. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.9687
Vancouver
Jang H, Lee SI, Kim HJ, Jung N, Zetterberg H, Blennow K, et al. Plasma Biomarkers and Clinical Outcomes in Early-Onset Dementia. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.9687. PMID: 42054026.
BibTeX
@article{jang2026-42054026,
author = {Jang, Hyemin and Lee, S I and Kim, Hee Jin and Jung, Na‐Yeon and Zetterberg, Henrik and Blennow, Kaj and Apostolova, Liana G. and Moon, So Young and others},
title = {{Plasma Biomarkers and Clinical Outcomes in Early-Onset Dementia}},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.9687},
pmid = {42054026},
url = {https://doi.org/10.1001/jamanetworkopen.2026.9687}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A total of 322 participants with p-tau217, GFAP, and NfL analyses were stratified into the EOAD or FTD group based on their diagnosis.
- The EOAD group (n = 245) had a mean (SD) age of 61.8 (5.4) years and included 163 females (66.5%), while the FTD group (n = 77) had a mean (SD) age of 65.1 (7.3) years and included 45 females (62.3%).
- In the EOAD group, higher log2-transformed baseline p-tau217, GFAP, and NfL were each associated with faster decline in the MMSE score (association estimate [SE], -0.390 [0.127], P = .002; -0.775 [0.164], P < .001; and -0.679 [0.182], P < .001, respectively) and the CDR-SB score (estimate [SE], 0.401 [0.099], P < .001; 0.535 [0.126], P < .001; and 0.693 [0.122], P < .001, respectively).
- In the FTD group, GFAP and NfL were associated with MMSE decline (estimate [SE], -2.118 [0.566], P < .001 and -2.360 [0.428], P < .001, respectively), whereas p-tau217 was not (estimate [SE], 0.071 [0.418], P = .87).
- No biomarker was associated with FTLD-modified CDR-SB score change.
Why it matters
In 245 people with early-onset Alzheimer's disease, higher baseline p-tau217, GFAP and neurofilament light were each linked to faster decline in cognitive scores, and all three markers rose over time. In the 77 people with frontotemporal dementia, GFAP and neurofilament light were linked to decline but p-tau217 was not.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants245
- Effect size66.5%; 62.3%
- Evidence strengthModerate
How this study scored 54/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 52 of the 96 points we could judge it on, which is 54 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Network Open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 245 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Hee-Jin Kim holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42054026) |
| Free to read | 2 / 2 | Free to read |
| Points | 52 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 52 of the 96 points we could judge it on is 54 out of 100. |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2026.9687
- PubMed: 42054026
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.